Open Access
Subscription Access
Understanding the Pharmacology of Chelators
Abstract
Chelators show a unique capability to bind with metal ions, impacting many physiological processes and offering therapeutic benefits in diverse mechanical conditions. The author provide more information regarding the pharmacology of chelators, exploring their mechanisms , applications and potential future developments. Chelation bind with metal ions,forming stable complexes that prevent the metal ions from participating in unwanted reactions. Clinical applications of chelation include heavy metal poisoning,viren overload disorders, radio pharma ceuticals and anti cancer properties. Finally it is concluded that the pharmacology of cheater’s encompass a wide array of applications, ranging from treating heavy metal poisoning in exploring novel avenues particularly in cancer and neuro degenerative disorder therapy.
References
Wax PM. Current use of chelation in American health care. J Med Toxicol. 2013 Dec;9(4):303-7. [PMC free article] [PubMed]
Markowitz ME, Rosen JF. Need for the lead mobilization test in children with lead poisoning. J Pediatr. 1991 Aug;119(2):305-10. [PubMed]
Sakthithasan K, Lévy P, Poupon J, Garnier R. A comparative study of edetate calcium disodium and dimercaptosuccinic acid in the treatment of lead poisoning in adults. Clin Toxicol (Phila). 2018 Nov;56(11):1143-1149. [PubMed]
Corsello S, Fulgenzi A, Vietti D, Ferrero ME. The usefulness of chelation therapy for the remission of symptoms caused by previous treatment with mercury-containing pharmaceuticals: a case report. Cases J. 2009 Nov 18;2:199. [PMC free article] [PubMed]
Lamas GA, Issa OM. Edetate Disodium-Based Treatment for Secondary Prevention in Post-Myocardial Infarction Patients. Curr Cardiol Rep. 2016 Feb;18(2):20. [PubMed]
Fulgenzi A, Ferrero ME. EDTA Chelation Therapy for the Treatment of Neurotoxicity. Int J Mol Sci. 2019 Feb 26;20(5) [PMC free article] [PubMed]
Sears ME. Chelation: harnessing and enhancing heavy metal detoxification—a review. ScientificWorldJournal. 2013;2013:219840. [PMC free article] [PubMed]
Porru S, Alessio L. The use of chelating agents in occupational lead poisoning. Occup Med (Lond). 1996 Feb;46(1):41-8. [PubMed]
Kim HC, Jang TW, Chae HJ, Choi WJ, Ha MN, Ye BJ, Kim BG, Jeon MJ, Kim SY, Hong YS. Evaluation and management of lead exposure. Ann Occup Environ Med. 2015;27:30. [PMC free article] [PubMed]
Treatment guidelines for lead exposure in children. American Academy of Pediatrics Committee on Drugs. Pediatrics. 1995 Jul;96(1 Pt 1):155-60. [PubMed]
Thomas DJ, Chisolm J. Lead, zinc and copper decorporation during calcium disodium ethylenediamine tetraacetate treatment of lead-poisoned children. J Pharmacol Exp Ther. 1986 Dec;239(3):829-35. [PubMed]
Lanigan RS, Yamarik TA. Final report on the safety assessment of EDTA, calcium disodium EDTA, diammonium EDTA, dipotassium EDTA, disodium EDTA, TEA-EDTA, tetrasodium EDTA, tripotassium EDTA, trisodium EDTA, HEDTA, and trisodium HEDTA. Int J Toxicol. 2002;21 Suppl 2:95-142. [PubMed]
Baxter AJ, Krenzelok EP. Pediatric fatality secondary to EDTA chelation. Clin Toxicol (Phila). 2008 Dec;46(10):1083-4. [PubMed]
Schardein JL, Sakowski R, Petrere J, Humphrey RR. Teratogenesis studies with EDTA and its salts in rats. Toxicol Appl Pharmacol. 1981 Dec;61(3):423-8. [PubMed]
REUBER MD, BRADLEY JE. Acute versenate nephrosis; occurring as the result of treatment for lead intoxication. JAMA. 1960 Sep 17;174:263-9. [PubMed]
Refbacks
- There are currently no refbacks.